Sign inJoin waitlistJoin the waitlist

Melinda L. Telli

Associate Director of Clinical Research · Stanford Cancer Institute

Credentials: · · ·

History

Breast Cancer Program · Stanford Cancer Institute
2020–Present
Stanford University School of Medicine
Present

Research

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Clinical Cancer Research · 2016 · First of 25 authors · 899 citations
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage…
The Lancet · 2020 · 869 citations
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 759 citations

James Ford
23 papers
William Gradishar
17 papers
Sharon Giordano
16 papers
Matthew Goetz
15 papers
Allison Kurian
14 papers
Anthony Elias
14 papers
SI
Steven Isakoff
14 papers
Harold Burstein
13 papers
HS
Hatem Soliman
13 papers
MM
Meena Moran
13 papers
Sameer Patel
13 papers
LG
Lori Goldstein
12 papers

Grants

Stanford Cancer Institute
National Cancer Institute · P30
Project lead · $387.5K · Stanford University
2007–2027

Clinical trials

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Principal investigator · Withdrawn · Phase 2
Stanford University
2023–2024
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Principal investigator · Recruiting · Phase 2
Stanford University
2021–2031
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Principal investigator · Completed · Phase 2
Melinda Telli
2015–2022
Vitamin D and Breast Cancer: Does Weight Make a Difference?
Principal investigator · Terminated · Phase 2
Melinda Telli
2011–2015